219 related articles for article (PubMed ID: 16309172)
41. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid.
Wang Y; Veeraraghavan S; Cabral F
Biochemistry; 2004 Jul; 43(28):8965-73. PubMed ID: 15248754
[TBL] [Abstract][Full Text] [Related]
42. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
43. Deoxypodophyllotoxin triggers necroptosis in human non-small cell lung cancer NCI-H460 cells.
Wu M; Jiang Z; Duan H; Sun L; Zhang S; Chen M; Wang Y; Gao Q; Song Y; Zhu X; Zhang L
Biomed Pharmacother; 2013 Oct; 67(8):701-6. PubMed ID: 23896261
[TBL] [Abstract][Full Text] [Related]
44. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
45. Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence.
Hirai Y; Yoshimasu T; Oura S; Ota F; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Anticancer Res; 2011 Mar; 31(3):999-1005. PubMed ID: 21498728
[TBL] [Abstract][Full Text] [Related]
46. Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
Locke V; Davey R; Davey M
Cytometry; 2001 Mar; 43(3):170-4. PubMed ID: 11170102
[TBL] [Abstract][Full Text] [Related]
47. Cellular models of drug- and radiation-resistant small cell lung cancer.
Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
[TBL] [Abstract][Full Text] [Related]
48. Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines.
Han EK; Gehrke L; Tahir SK; Credo RB; Cherian SP; Sham H; Rosenberg SH; Ng S
Eur J Cancer; 2000 Aug; 36(12):1565-71. PubMed ID: 10930805
[TBL] [Abstract][Full Text] [Related]
49. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
50. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
51. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM
Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652
[TBL] [Abstract][Full Text] [Related]
52. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
Simoni D; Romagnoli R; Baruchello R; Rondanin R; Grisolia G; Eleopra M; Rizzi M; Tolomeo M; Giannini G; Alloatti D; Castorina M; Marcellini M; Pisano C
J Med Chem; 2008 Oct; 51(19):6211-5. PubMed ID: 18783207
[TBL] [Abstract][Full Text] [Related]
53. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
Chu SW; Badar S; Morris DL; Pourgholami MH
Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
55. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
Pettit GR; Rhodes MR; Herald DL; Hamel E; Schmidt JM; Pettit RK
J Med Chem; 2005 Jun; 48(12):4087-99. PubMed ID: 15943482
[TBL] [Abstract][Full Text] [Related]
56. Cytoskeletons and antimitotic agents developed in Japan.
Nishio K; Saijo N
Anticancer Drug Des; 1999 Apr; 14(2):133-41. PubMed ID: 10405640
[TBL] [Abstract][Full Text] [Related]
57. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Pesic M; Markovic JZ; Jankovic D; Kanazir S; Markovic ID; Rakic L; Ruzdijic S
J Chemother; 2006 Feb; 18(1):66-73. PubMed ID: 16572896
[TBL] [Abstract][Full Text] [Related]
58. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
Lobert S; Frankfurter A; Correia JJ
Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
[TBL] [Abstract][Full Text] [Related]
59. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
60. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
